NCT07542405Not yet recruiting
A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families
Kindred: Family Centered Approaches to Promoting Cascade Screening for Hereditary Cancer Syndromes Among African Americans
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
This clinical trial studies whether a web-based program, Kindred, works to improve the understanding of genetic cancer risk and cancer genetic testing in African American families. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or a family history of cancer means individuals are more likely to have a genetic change. If a genetic change is identified in a family, other relatives can choose to undergo hereditary cancer genetic testing to better understand their cancer risk. In families where a genetic change is not identified, or results are uncertain, relatives may also benefit from discussing their cancer risk with providers and, in some cases, getting hereditary cancer genetic testing themselves. Research has shown that African Americans are less likely than other racial groups to engage in cancer genetic testing. Kindred is an online tool that provides information so individuals can learn about their cancer genetic test results, how cancer genetic testing can help individuals and families understand their overall cancer risk (and strategies for reducing risk), and ways to talk with each other about cancer risk and health. This may be an effective way to improve the understanding of genetic cancer risk and cancer genetic testing in African American families.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 14 Apr 2026
- Start date
- 15 Jun 2026
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Diseases
- Ovarian cancer
- NCT number
- NCT07542405
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 15 Jun 2026 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- PROBANDS: No evaluation at U-M or other facility, or evaluation was more than one year ago, or received an evaluation more recently than the relative
Other illness
- PROBANDS: Did not receive cancer genetic testing
Other
- PROBANDS: Under 18-years-old
- PROBANDS: Does not speak or read English
- PROBANDS: Does not have internet access
- PROBANDS: Does not identify as African American or Black
- RELATIVES: Not a biological relative of proband
- RELATIVES: Under 18-years-old
- RELATIVES: Does not speak or read English
- RELATIVES: Does not have internet access
Who the study is looking for
- PROBANDS: Evaluation in the past one-year at the Breast and Ovarian Cancer Risk Evaluation Clinic (BOCRE) or Cancer Genetics Clinic, both located at the University of Michigan (U-M) Rogel Cancer Center who are positive for hereditary breast and ovarian cancer syndrome (HBOC) (BRCA1, BRCA2) or Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM); indeterminate negative; or variants of uncertain clinical significance (VUS). If more than one biological relative is known to have received an evaluation for and or completed germline testing for cancer risk, the relative who was evaluated the longest time ago to align with the tradition definition of a proband as defined by the National Cancer Institute (NCI), i.e., the first person identified as possibility having a genetic disorder and who may receive counseling or testing
- PROBANDS: \>= 18-years-old
- PROBANDS: Completed genetic testing for hereditary cancer syndromes, regardless of results
- PROBANDS: Able to speak and read English
- PROBANDS: Access to the internet
- PROBANDS: Identifies as African American or Black (may have additional race or ethnicity identities)
- RELATIVES: Biological relative of enrolled proband, regardless of testing completion or timing of testing
- RELATIVES: \>= 18 years old
- RELATIVES: Able to speak and read English
- RELATIVES: Access to the internet
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Rogel Cancer Center Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.